.

ࡱ>   bdfhj   !"#$%&'()*+,-./0123456789:;?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`acdefghijklmnopqrstuvwxyz{|}~Root Entry Fռ`?ȷ @Workbook SummaryInformation(DocumentSummaryInformation8 \p ;53 ;N:0G Ba==xx;V"8X@"1" Arial Cyr1" Arial Cyr1" Arial Cyr1" Arial Cyr1" Arial Cyr1" Arial Cyr1" Arial Cyr1"@ Arial Cyr1h8Cambria1,8Calibri18Calibri18Calibri1Calibri1Calibri1Calibri1?Calibri14Calibri14Calibri1 Calibri1 Calibri1Calibri1Calibri1 Calibri1Calibri1" Arial Cyr/#,##0"@.";\-#,##0"@."9#,##0"@.";[Red]\-#,##0"@.";#,##0.00"@.";\-#,##0.00"@."E #,##0.00"@.";[Red]\-#,##0.00"@."k*3_-* #,##0"@."_-;\-* #,##0"@."_-;_-* "-""@."_-;_-@_-k)3_-* #,##0_@_._-;\-* #,##0_@_._-;_-* "-"_@_._-;_-@_-{,;_-* #,##0.00"@."_-;\-* #,##0.00"@."_-;_-* "-"??"@."_-;_-@_-{+;_-* #,##0.00_@_._-;\-* #,##0.00_@_._-;_-* "-"??_@_._-;_-@_- 0.00000#"0";"0";"5B"5"AB8=0";"AB8=0";">6L")":;";":;";"K:;"Y*[$ -2]\ ###,000_);[Red]\([$ -2]\ ###,000\)                                                                        , *  P  P     a>  ff             `  + )   8@ @ 8@ @ 8@ @ " " ||CnS"}A} 0_);ef$ -2}A} 0_);ef$ -2}A} 0_);ef$ -2}A} 0_);ef$ -2}A} 0_);ef$ -2}A} 0_);ef $ -2}A} 0_);L$ -2}A} 0_);L$ -2}A} 0_);L$ -2}A} 0_);L$ -2}A} 0_);L$ -2}A} 0_);L $ -2}A} 0_);23$ -2}A} 0_);23$ -2}A} 0_);23$ -2}A} 0_);23$ -2}A}  0_);23$ -2}A}! 0_);23 $ -2}A}" 0_);$ -2}A}# 0_);$ -2}A}$ 0_);$ -2}A}% 0_);$ -2}A}& 0_);$ -2}A}' 0_); $ -2}}( ??v0_);̙$ -2,000?_@_ @_- }}) ???0_);$ -2???,000????_@_ ???@_- ???}}* }0_);$ -2,000?_@_ @_- }A}- 0_);$ -2}A}. 0_);?$ -2}A}/ 0_);23$ -2}-}0 0_);}U}1 0_);$ -2,000}}2 0_);$ -2???,000????_@_ ???@_- ???}-}3 0_);}A}4 e0_);$ -2}A}5 0_);$ -2}-}6 0_);}x}70_);$???,0 ????_ ???@_}A}9 }0_);$}-}: 0_);}A}= a0_);$ 20% - :F5=B1M 20% - :F5=B1 ef % 20% - :F5=B2M" 20% - :F5=B2 ef % 20% - :F5=B3M& 20% - :F5=B3 ef % 20% - :F5=B4M* 20% - :F5=B4 ef % 20% - :F5=B5M. 20% - :F5=B5 ef % 20% - :F5=B6M2 20% - :F5=B6  ef % 40% - :F5=B1M 40% - :F5=B1 L % 40% - :F5=B2M# 40% - :F5=B2 L湸 % 40% - :F5=B3M' 40% - :F5=B3 L % 40% - :F5=B4M+ 40% - :F5=B4 L % 40% - :F5=B5M/ 40% - :F5=B5 L % 40% - :F5=B6M3 40% - :F5=B6  Lմ % 60% - :F5=B1M 60% - :F5=B1 23 % 60% - :F5=B2M$ 60% - :F5=B2 23ٗ % 60% - :F5=B3M( 60% - :F5=B3 23֚ % 60% - :F5=B4M, 60% - :F5=B4 23 % 60% - :F5=B5M0 60% - :F5=B5 23 %! 60% - :F5=B6M4 60% - :F5=B6  23 %":F5=B1A:F5=B1 O %#:F5=B2A!:F5=B2 PM %$:F5=B3A%:F5=B3 Y %%:F5=B4A):F5=B4 d %&:F5=B5A-:F5=B5 K %':F5=B6A1:F5=B6  F %(2>4 u2>4  ̙ ??v% )K2>4uK2>4  ???%????????? ???* KG8A;5=85 KG8A;5=85  }% +&5=56=K9,. 5=56=K9 [0]- 03>;>2>: 1K 03>;>2>: 1 I}%O. 03>;>2>: 2K 03>;>2>: 2 I}%?/ 03>;>2>: 3K 03>;>2>: 3 I}%230 03>;>2>: 4= 03>;>2>: 4 I}% 1B>3KB>3 %OO)2>=B@>;L=0O OG59:0>=B@>;L=0O OG59:0  %????????? ???30720=8570720=85 I}%4 59B@0;L=K9I 59B@0;L=K9  e%$1KG=K95;>E>9?;>E>9  %6 >OA=5=8595 >OA=5=85 %7 @8<5G0=85n @8F5=B=K9%9!2O70==0O OG59:0U!2O70==0O OG59:0 }%-:"5:AB ?@54C?@5645=8OO "5:AB ?@54C?@5645=8O %;* $8=0=A>2K92K9 [0]=%>@>H89A%>@>H89  a%XTableStyleMedium9PivotStyleLight16`8AB1  ;Mg    D b< {+KƧ ѡKy n {+KƧ ѡKyPNG  IHDRD\YPLTE޽޵ν޵Žޭޭ֥֥֜֔֔ΔΌΌ΄ń{{sssk{{{css{ZsZsRkkRkkJkkJcc{cJcBZBZ{Z:Z:RsR:R1R)JsJkJ)BkBcJ)J!B!B:c::c:1Z)Z)R!R!JRbKGDH cmPPJCmp0712Hs IDAThCZOXMWThNXAh!0SCSݫKzAPvӇ+e{óZDV󔈞U !cvycT 5T{fӰ!q]VCF >ruT.,ڧת޹ޜ_jՀڸ 9uPt@|~,8Nw{wR7bĔQzԿT1+*8.3RVu ӢJIݮ}*9 kuڮ&xEƀAR Rܫ1 &HX'Biwʰ4Tea `C*'5y>֤dHAM v'vS ئԊ4`P ;jW xى;E X)jRJrIi?|gToMgh5t=UXC+dA6,\őyNUurΟz>bo'XzPrhǰZ*vZCݡ o[&Uº_8*TqjUPs7|j0>ݪY_(o*a8jI-}UʓBGKP}k`~SBef%IiS[e T5JL7{(k?!BDnjwJYyR fcո.ibjqZub1-(BČmBÍt邪Q"UP:Sk9&1b\ 1_,_$z{XQALn ԽmrwYg˒l /Yk;+9} q/PDCn*6wýt[EdEJ"Ӕmcx(Ǖm5|jy1(Usv=G֫-O~-w8خH}vh,r㢈-;7jj!ԢPZ-\y|zfݝ)a : aF~ [LC(T`ܺSU^3]D0JbX^ G蔕"GyV1P3uף Ps8i]k6Į6z?_5.͙>9m벛^*s<KM-p:dEV֪Wy/#XtYtZ&lIin$bj 5.#E kZ`% .r+bmIE^!i<ЀhWhk ӀO@7Au,s5^%RBPs҅]kY1`#Pw_) SO W$9[Vffncx*hN9gzqOfoP!n@Fʏ|KJ6\^%p* iwx_3ߒ^ EC?d Oe ^]&&V*$PvhB.AAbVDsMU@48AB>2 (Hartmann)(?B5G:0 I8/?@>25:/DMAB (@54?@8OB85 $-!")4?B5G:0 5@2>9 >I8 (B@0=A?.-=>2K9 >;>)#@020 B01 10<3 !30 (Aventis Pharma)#@020 B01 209:0 50<; ("25@A:0O D0@<. D01@8:0); :0?A. 1002A:89 28B0; B01. ?/> 50<3 !10 (0;LE8<D0@AC;LD0= :@5= @5B0@4 B01. ?/> 1,5= B01. ?/> 2,5<3 !30 (Servier)@@ B01 0,05 !30 (Searle)*@B578= B01 22A:89 28B0-0:B82 10;L70< 3@520NI89 20,0 ( )2@B@>28B 10;L70< ?8B0NI89 100@B 54A5@28A)4@B@>28B 10;L703@520NI89 10078;5= 0<?. 160<3 278;5= 35;L 5% BC10 503@ (Dompe Farmaceutici SPA)3@B@>78;5= :0?A. 32078;5= A?@59 15% 10;;>=G8: 25<; 4/=0@C6=. ?@878;5= AC??. 160D>>= B01 !100 (0B5@80 548:0)$@B@>F8= 1,6 n60 B01; (&  $0@F8= 35;L A ?G5;. O4>AB5>E>=4@. 50F8= B01;. 1,63@. !36 ( &  $ )(@CB8; 3;. :0?;8 0,5% 5<; (Ankerpharm)2A:;570=  :@57=K9 75 3@ BC10 ( >AA8O)A:;570=  B01 500@18=>20O -B0 5% 2<; E8@18=>20O :-B0 0<?. 10% 2A8=B57)*A:>@18=>20O :-B0 4@. 50D0@@18=>20O :-B0 4@. 50D0@@B 4;O =>3" :@5< 1KAB@. 459AB28O 125<; (Laboratoires Expanscience)=MUSTELA BEBE 9 <5A :@5B @0AB.42>9= 459AB. 200 <; ($@0=F8O)GMUSTELA BEBE 9 AAB. D83C@K ?>A;5 @>4>2 200<; ($@0=F8O)6MUSTELA BEBE 9 <5AOF52 :@5< 4;O 3@C48 125 <; ($@0=F8O)cMUSTELA BEBE 9 <5AOF52 :@5B @0ABO65: 8=B5=A82=. 4-8O 7570B (Laboratoires Expanscience)QMUSTELA BEBE Hydra Bebe :@5< 4/;8F0 C2;06=. 40<; BC10 (Laboratoires Expanscience)8MUSTELA BEBE Stelactiv :@54 ?>43C7=8: 75<; ($@0=F8O)6MUSTELA BEBE STELATOPIA :@5<-M<C;LA8O 200<; ($@0=F8O)IMUSTELA BEBE STELATOPIA  4;O 20== 250 ;L4 :@5< 40<; (Laboratoires Expasuns)7MUSTELA BEBE :@54 ?>43C7=8: 50<; ($@0=F8O)<MUSTELA BEBE  4/<0AA060 45BA:. 100<; D;.A?@59 ($@0=F8O)EMUSTELA BEBE ?5=0 4/20==K @0AA;01;. 200<; (Laboratoires Expanscience)?MUSTELA BEBE A0;D5B:8 4;O ;8F0 ! 25 (Laboratoires Expanscience)*MUSTELA BEBE H0<?C=L 45BA:.200<; ($@0=F8O)#-?0@ 0M@. 1253 (SCAT Laboratories)'10:B0; 0<?. 400<3 5<; !10 (Lek Pharma)#10:B0; B01. 400 8 4:A @-@ 4/8=D. 400<3 D;. 250:A B01. ?/> 400<3 !5 (Bayer AG (@5F5?B.))N280-@5 :0@0?0B. !15 (>B C:0G820=8O 2 B@0=A?>@B5) (0B5@80 548:0)@280-@5 B01. !20 (>B C:0G820=8O 2 B@0=A?>@B5) (0B5@80 548:0)%30?C@8= 4@. 100<3 !60 (Slovakofarma)-30?C@8= @5B0@4 B01. 400 600@<0 :0?A. 0,24 !60 ($0@<0  )/40;0B ! 0?84- 5B0@4 20 %30 (Bayer))40;0B-! 30<3 !28 (Bayer AG (@5F5?B.)))420=B0= :@5< 0,1% BC10 153 (Schering AG)1420=B0= <07L 153 ("! #$-'#  !...)0420=B0= <07L 68@=0O 0,1% BC10 153 (Schering AG)<420=B0= M<C;LA8O 4/=0@C6. ?@8<. 0,1% BC10 203 (Schering AG)+45;LD0=-M784@5:A B01 ! 10 (Novartis Pharm)245;LD0=-M784@5:A B01. !250 (Novartis Enterprises)245;LD0=-M784@5:A B01. !30 (Simpex Pharma Pvt Ltd)94@5=0;8=0 3/E; 0<?. 0,1% 1A:.M=4>:@8==K9 702>4)64@80=>; :0?;8 =070;L=K5 4/27@>A;KE D;. 10; :0?;8 =070;L=K5 4/45B59 D;. 10<; (Zdravle)528B :0?A. 0,23 !10 (N<8 )528B :0?A. 0,23 !10 ($5@59=)(70;5?B8= (#) 0.13 "01. %50 (< @30=8:0)$70;5?B8= B01. 0,0253 !50 (@30=8:0)-78B@0; :0?A 250 :A :0?A. 250 ?8@0< (=0 100 AA8O):7>?B 3;. ACA?. 1% D;. 570B>@>@=528I5 ?0G:0 503 (!"-548D0@<)@=528I5 D8;LB@-?0:5BK 1,53 !20 (@0A=>3>@A:89 7-4  !)*:0B8=>; 5 10; 5 10<3 !90 (Merz)0:20-0@8A :0?;8 =070;L=K5 4/45B59 10<; (Jadran)4:20-0@8A A?@59 30A0 (2>40 @A:0O) (Jadran)\:2045B@8< 15000<5/<; 10@0; ?@8@ D>@B5 A@-2> 4/?@>;>AB8 =>A0 200?>;8A  35;L 8 ?>;8A):28@8= 50 15AB8:0)/Boehringer Mannheim)'::C?@> B01. ?/> 10 B01. ?/> 20<3 !30 (Parke-Davis)&:@845@< " :@5; B01. 12,5; B01. 25:A840=B :0?A. 0,390 3.!30 ($0@5:B).:B8?>; 3;07=K5 :0?;. 0,007% 5<;. D; ($ )/:B8D5@@8= 300<3 0?A. %50 (Ratiopharm/Merckle)*:B8D5@@8= :0?;8 30<; (Ratiopharm-Merckle)+:B8D5@@8= :0?A. 3002538= 0<? 52538= 0<?. 22538= 0<?. 400<3 102538= 35;L 20% 203 (Nycomed Pharma)&:B>2538= :@52538= @-@ 4/8=D. A 3;N:>7>9 10% D;. 2502538= @-@ 4/8=D. A E;>@84>< =0B@8O 10% D;. 2502538= @-@ 4/8=D. A E;>@84>< =0B@8O 20% D;. 2502538= B01 ?/> 200 2538= B01. ?/> 2002538= B01. ?/> 2002538= B01. ?/> 200B5:A)6:B@0?84 =< @-@ 4/8=. 10054\<; D;. 10 !50 (Solvay pharma)1;5@0=0 10;L70<-A?@59 D;.50 <; 4/<C6G8= (5@B5:A)&;:08= 3;. :0?;8 0,5% D;. 15!B>? (;:>$@8) :0?A. ! 60 (Altera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iotechnos SA);L10@5; B01. 1<3 !10 (Egis);L10@5; B01. 1<3 !30 (Egis)P;L1C<8= 10% 10035=  :0B5@8=1C@3A:>5  ?> ?@-2C 10:?@5?0@0B>2)/;L1C<8= @-@ 4/8=D. 10% 1002A:89 %D7)I,$  (.& )"Alfa Herb"500<3!90 :0?A (Nittany Pharmaceuticals Inc)!;LD0 3 0.25<:3 0?A. %60 (Teva)5;LD0 3-"520 :0?A. 0,25<:3 !30 (Teva Pharmaceutical)2;LD0 3-"520 :0?A. 1;-!0 :0?A. !30 (Panacea Biotec) <0@8; B01. 1<3 !30 (Hoechst AG)%<0@8; B01. 2<3 !30 (Aventis/Hoechst)$<0@8; B01. 3<3 !30 (Aventis Pharma)%<0@8; B01. 3<3 !30 (Aventis/Hoechst)915=5 -@ /8=. 15<3/2<; <?. %5 (Ratiopharm/Merckle)@15=5 @-@ 4/?@85<0 2=CB@L 7,5<3/<; D;. 40<; (Ludwig Merckle)315=5 A8@>? 15<3/5<; 100<; (Ratiopharm-Merckle)+15=5 A8@>? 15<3\5<; 100<; (Ratiopharm),15=5 B01. 30<3 !20 (Ratiopharm-Merckle))35:A0; :0?A. @5B0@4 75<3 !10 (Hexal)!35:A0; B01. 30<3 !20 (Hexal)"<83@5=8= B01. 100D0@<)!<83@5=8= B01. 50D0@<)"<8:0F8= AC;LD0B D;. 0,53 (!8=B57)2 125<3 !10 (0;LE8<D0@</0AB5@;5:)1 125<3 !6 (0;LE8<D0@</0AB5@;5:)1 60<3 !10 (0;LE8<D0@</0AB5@;5:)+ 0.1253<  n6 (,%$  )2<8=078= - .!. (F) 1002A:89 8B)1<8=078= - .!. (F) 502A:89 8B)-<8=078= - .!. 252A:89 8B):5-=>: B01. ?/> 5025=8O /5:B>@-$0@AA8O)&90-60-90 B01. 0,53 !150 (>@B ;NA)2Johnson"s Baby  100<; $;. (Johnson @ Johnson)2Johnson"s Baby  200<; $;. (Johnson @ Johnson)=Johnson"s Baby  5@54 A=>< 200<; $;. (Johnson @ Johnson)9Johnson"s Baby  A @>9 200<; (Johnson @ Johnson)7Johnson"s Baby  5@54 A=>:>@B87>=- 8EB5@ !CA?. 4/8=. 5<; :>@B87>=>20O E8<8:):>@B87>=>20O @>AB@>8B. 7-4)-84@>?5@8B B01. 1,53 !8 ("0BE8<D0@; 7 203. A25G8 100<3 !7 (Sagmel Inc.)E5;L :0?;8 D;. 30<; (Biologische Heilmittel Heel GmbH)+8=8?@0; 0<?. 10<:3 2<; !5 (Nycomed Pharma)(8=8?@0; B01. 0,5@ 35;L 403 (Beaufour Ipsen International)&8=:>@ D>@B :0?A. !30 (Beaufour Ipsen).8=>-?520@8; AC??. 150-?520@8; AC??. 50-B@02>35= >2C;C< 203. AC??. 600D>@B :@5< 2038=0;L=K9 20@ 53 (Gedeon Richter)%8?>7>;L 0M@>7>;L 573 (;B0928B0:A5= :0?A. 0,253 !30 (;8D5= >@?>@0F8O ))8?>@0<8= B01. 20<3 !10 ($0@B80784 B01. 25B80784 B01.100= 35;L 503 (8>:>= ! )$8@C4>?@>:B 35;L 503 (8>:>= ! );8AB03;>1C;8= ACE>9 0<?. 1<; !5 A @-;535=  $#)'8AB0= :0?A ?@8 0;;5@388 0,23 !36 (!);8AB>48; B01. 200<3 !50 (Gedeon Richter 5=3@8O /$0@3@04)4;80B8;8= 0<?. 1000 <3 4<; !3 (Italfarmaco/$0@@)+;80B8;8= 0<?. 13 !3 (Italfarmaco/$0@@)0;80B8;8= :0?A. 400<3 !14 (Italfarmaco/$0@@)1;81> 2,5<3/400 2,5<3/400<3 !40 (Laboratori Guidotti S.p.A./Menarini Group);84801 B01. 80;C10O ?>@>H>: 1003 (>;8!5@28A-));8=0 @>7>20O ?>@>H>: 1003 (>;8!5@28A-)(8B@C< @5=0B0; B01. !30 (Unipharm Inc.)38B@C@B5 B01. ?/> !100 (Unipharm Inc.)28B@C@B5 B01. ?/> !30 (Unipharm Inc.)58B@C< B01. !30 (Unipharm Inc.) 8B@C< B01. !100 (Unipharm Inc.)8B@C< B01. !30 (Unipharm Inc.),8B@C !100 (Unipharm Inc.)'8B@C %100 (Unipharm)18B@C< B01. !100 (Unipharm Inc.)08B@C< B01. !30 (Unipharm Inc.)+8B@C !100 (Unipharm Inc.)&8D5@>= =)$8D5@>=-1 A25G8 150000 !10 ($5@>=)$8D5@>=-2 A25G8 500000 !10 ($5@>=)%8D5@>=-4 A25G8 3000000 !10 ($5@>=)/( <8=5:A8; 4/<C6G8= 0<?.18 HB. (Vichy lab.)C( 0;L70?>;0A:820B5;L ?8B0B. 2>AB0=02;. D; 1504>@0=B-H0@8: 4/GC2AB2. :>68 D;. 50= 35 30 1M=78 !200 (Mucos Pharma)%>1M=78 !800 (Mucos Pharma)4>1M=78:@. :8H5G=>@. >1. %40 (Mucos Pharma)/>1M=78 n200 35@40 /8=. 5<; <?. %10 (0;LE8<D0@40 /8=. 5<; 2 )8>40 4/8=J5:F89 0<?. 235=  8><54 5@40 4/8=J5:F89 0<?. 535=  $#)+>40 A28=F>20O 100A:>2A:0O D0@40 '5<5@8G=0O 40A;02A:0O D.D.),>;LB0@5= 0<?. 75<3 3;LB0@5= A25G8 100;LB0@5= A25G8 25;LB0@5= A25G8 50;LB0@5= B01. ?/> 25;LB0@5= M;LB0@5= M;N25= @-@ 4/8=D. 6% D;. 500@<8= 100 6 B01 %24 (Cadila Pharmaceuticals Ltd.)1@540 E8B>70= :0?A.!60 ($0@@ @>40:H=)"C:0 2C:0 B01. 550:>@?)7M9B09 :0?A. 500 B01. ?/> 500<3 !3 (Panacea Biotec)@ )60;028B ?>@. 4/8=. 100<3 D;. 10@ &! ) 0;07>;8= 0,05% D;. 10;8= 0,1% D;. 10<; (Polfa)=0;8C<-E5;L :0?;8 D;. 30?5@84>; 0<?. 5<3 1?5@84>; B01 5=D0@4a:H= )?5@84>;- 0B8>D0@< :0?;8 2<3/<; D;. 30<; (Ludwig Merckle)=0;AB5=0 :0?;8 4/2=CB@. ?@8<. D;. 204JO7KG=K5 3>?0B8G5A:85 !12 1;8AB5@K (Bittner Richard Gmbh) 0<0:B>@ )00<0<5;8A A:>2A:0O D0@<.D-:0)(0<8<C=(@-@ 4/8=.2/2 10% 25= :0?;8 5 9:0 25AA8O).0;5@80=K 0AB>9:0 25<; $;. (5@<D0@<0F8O ):0;5@80=K M:AB@. B01. 20<3 !10 ($0@<A:E8<D0@<)*0;5@80=K M:AB@. B01. 20A8=B57);0;84>; A 3;N:>7>9 B01. 0,063 !10 (ICN 5:A@54AB20 3.C@A:)10;84>; A 3;N:>7>9 B01. 0,063 !10 (@18BA:89 %$)00;84>; B01. 0,063 !10 (ICN 5:A@54AB20 3.C@A:)?0;84>; B01. 0,063 !10 ($0@:>@48= 20:>@48= 50:>@48= :0?;8 D;. 20:>@48= :0?;8 D;. 50A8=/ ;8>D. 4/?@83. @-@0 2/2 13 %1 (!8=B57)30=:>D. ?>@. 4/8=. D;. 0,53 !1 (M=A $0@<)!0@D0@5:A 3<54 B01. 2,5<54 B01. 2,5<3 !50 (Nycomed Danmark)(0B0 38385=8G5A:0O =5AB5@. 503 (;5?8:8),0B0 783-703 =/AB5@. 1003 020B0).0B0 54.8385=8G5A:0O 20B0))0B0 =5AB5@8;L=0O :8?=0O 15:3 (83@>20B0)70B0 !B5@8;. %8@C@38G5A:0O "0;KH" 1003 (83@>20B0 )G0B0 E8@C@38G5A:0O =5AB5@8;L=0O 1003 E;>?:>20O "020B0 )>0B0 E8@C@38G5A:0O =5AB5@8;L=0O 1003 E;>?:>20O (83@>20B0 )80B0 E8@C@38G5A:0O =5AB5@8;L=0O 2503 E;>?:>20O (;5?8:8)-0B0 E8@C@38G5A:0O =5AB5@8;L=0O 503 (;5?8:8)A0B0 E8@C@38G5A:0O AB5@8;L=0O 1003 <548F8=A:0O (/  "):0B0 E8@C@38G5A:0O AB5@8;L=0O 1003  )>0B0 E8@C@38G5A:0O AB5@8;L=0O 2503 20B0 ):0B0 E8@C@38G5A:0O AB5@8;L=0O 503 "020B0 )=0B=K5 48A:8 Bel Premium 2;06=K5 !30+3 A 0;>M 25@0 (Hartmann)G0B=K5 48A:8 Bel Premium 2;06=K5 !30+3 A @A:8<8 <8=5@0;0@5O (SHENZHEN TOP ONE INDYSTRY)C0B=K5 48A:8 ! 80 Soft Care @>D8 >@5O (SHENZHEN TOP ONE INDYSTRY)0B=K5 48A:8 OLA !50 (Celltex)-0B=K5 48A:8 :@C3;K5 !80 Helen Harper (Ontex)90B=K5 ?0;>G:8 (40052/4352) (2 ?0:5B5) %100 (8@ 5BAB20)90B=K5 ?0;>G:8 Bel Premium !300 (?;0AB8:.1>:A) (Hartmann)!0B=K5 ?0;>G:8 OLA !100 (Celltex)$0B=K5 ?0;>G:8 G:8 G:8 A >3@0=8G8B5;5< !40 (8@ 5BAB20)'0B=K5 H0@8:8 OLA F25B=K5 !40 (Celltex)%578:0@ 5 <3 ! 30 (/#' .  ..)5;0:A8= B01. 75<3 !28 (Egis)&5;0D0:A B01.75:B>@0 B09AA0 n20 :0?A ("  "!! "#   %, 5@<0=8O):5=70 :0?;8 4/2=CB@. ?@8<. D;. 207>; 1,63 B1. ?/> !36 NEW (!)"5=>7>; 1,63 B1. ?/> !60 NEW (!).5=>7>; 35;L ?@8 20@8:>75 50:>@A5B 50;09D 35;L ( >AA8O)+5=>?;0=B @5B0@4 B01. !20 (Willmar Schwabe)05=>@CB>= 1000@CB>= 35;L 2% 403 (Novartis Consumer Health)45=>@CB>= :0?A. 300D5@ 4/8=. 2/2 100<3 0<?. 5<; !5 (Vifor) 5=B5@ B01. 500;8= 0M@. 200 4>7 (Glaxo-Wellcome/Polfa)'5=B>;8= 0M@. 200 4>7 (GlaxoSmithKline)B5=B>;8= 51C;K @-@ 4/8=30;. 2,5<3 0<?. 2,5<; !20 (Glaxo-Wellcome)*5@15=0 50 AC4K" (LN<M= CA)&5@:A B01. 100-B0:A8D5= 0,02 n30 B01; (5@>D0@-B0:A8D5= 0,02 n30 B01; (5@>D0@H?8;0:B>= B01. 25;5=A:>5 D0@H?8@>= :0?A. 100<3 !30 (GedeonH?8@>= :0?A. 50H?8@>= B01. 25@>402>: 8 ?0?8;;>84K)L5@A0B8A /84>:08=/ B@0=A45@<. B5@0?52B. A8AB5E5;L :0?;8 30?0B8O) (Biologische Heilmittel Heel GmbH)75@B83>E5;L B01. !50 (Biologische Heilmittel Heel GmbH)G5AA5; CM $ :0?A. 250  !50 (Alfa Wass B0;8O /$0@@ ?@>40:H= )T5AA5; CM $ @-@ 4/8=. 600  2<; 0<?. !10 (Alfa Wass B0;8O /$0@@ ?@>40:H= ) 5B>@>= 5 :0?;8 2% 20=)>5B>@>= D;0:>=-:0?5;L=8F0 2% 204>@0AB2>@8@>= D;0:>=-:0?5;L=8F0 20= )"5G5@=55 4@065 !100 () (8>:>@)&803@0 B01. 0.053 n4 ($  $ &/)!803@0 B01. ?/> 100 25 504 )181@>F8; 35;L BC10 123 (Novartis Consumer Health)F8; :0?;8 =070;L=K5 D;. 15F8; A?@59 =070;L=K9 10; A25G8 4/4 !12 (Hell):830=B>; (>;5:0;LF8D5@>;) <0A;. @-@ D;. 10<; !1 (E.Merck)"845AB8< 84K)*848A8: 3;. 35;L 103 BC10 (Bausch & Lomb.)878= 3;. :0?;8 15 10;0=A B01. !60 (Hankintatukku OY)%8:0A>; B01. 15A8=B57 )/8;L?@0D5= !>;NB01 1000 500<3 !10 (Yamanouchi Europe B.V./Yamanouchi Pharma S.p.A.)B8=8;8= (0;L70AB0:>2A:>3>) 1003 =0@C6=>5 (%8<?;5:B)W8=8;8= (10;L70AB0:>2A:>3>) 503 4/=0@C6. ?@8<. (070=A:0O D0@B@>?8; :0?A ! 50 (0=>=D0@40:H=)-8=?>F5B8= 0<?. 0,5% 2B5:A/)I8=?>F5B8= :>=F. 4/?@83. @-@0 4/8=D. 5<3/<; 0<?. 2B5:A/)#8=?>F5B8= B01. 5<3 !20 (! D0@F5B8= B01. 5;5=A:>5 D0@;5:A :@5< 50;5:A B01. 200; 35;L BC10 53 (Merz)8A:0;L48:A B01. !20 (Egis)8A:5= B01. 5<3 !30 (Egis)78B0 + "Vita B-Plus" !60 (Nittany Pharmaceuticals Inc)18B0 "0C@8= (Vita Taurine) :0?A 500 4C@>; 3;. :0?;8 10<; (Ciba Vision)+8B010:B 3;. :0?;8 0,05% 10<; (Ciba Vision)"8B030<<0 2<; n5 02-)58B0@0B>@8O @5A=O:>20)48B0<8= F 99 B0;L:-:@5<(45BA:89) 50<; ($0@= )/8B0<8=  100-5=B820 100<3 0?A. %30 (Zentiva)/8B0<8=  200-5=B820 200<3 0?A. %30 (Zentiva)/8B0<8=  400-5=B820 400<3 0?A. %30 (Zentiva)(8B0<8=  :0?A. 200 !100 (Sagmel Inc.)(8B0<8= ! H8?. B01. 2508B068 (!B@5;5F D8@= 25@>1:0/ (8B>= 10;L70< 0@020520 D;. 50= ;N:A 15AB AC??. @5:B. !10 (86D0@< )%8B0A?5:B@C !30 (5@>D0@=: ?>;828B0<?;5:A :0?A. 180D0@<0 ))8B@C !30 (Unipharm Inc.))8B@C %30 (Unipharm)(8B@C !60 (Unipharm Inc.)(8B@C@B5 "01.?/> %30 (Unipharm)08B@C< 8B0<8=  400 :0?A. !60 (Unipharm Inc.):8B@C< 0;LF8C< + 8B0 !100 (Unipharm Inc.)-8B@C !30 (Unipharm Inc.)08A0:>48; A25G8 1048;-E5D0@< 4@065 5; B01 480; B01. 12030< 1030< 5<3 !30 (Worwag Pharma)&8D84C< C;LB8-1 C?. 25 3 (<D8B0 )(8D84C< C;LB8-2 0,25 3 !30 (<D8B0 )+8D84C< C;LB8-3 :0?A 0,43 !30 (<D8B0 ).8D84C@. ?0:5BK !30 (0@B=5@ )08D84C ?;NA)68D84C@ ?0:5BK !10 4/2= ?@8< (0@B=5@ )+8D84C@. 5 4>7 !30 (0@B=5@ ))8D84C9 54>7 !10 (-:>?>;8A)-8D84C9 A25G8 !10 (0@B=5@ )18D84C7 !10 (8:@>35=  $#)38D84C@B5 ?>@. ?0:5BK !30 (0@B=5@ )%8D8:>; D;. 5 4>7 !10 (8>A:20)B8D8;87 (83M;) ;8>D8;870B 4/?@83. @-@0 D;. 54>7 !10 ($5@<@;8= 1303 ( ?;NA ))8H>D8B 10;L=5>;>38G5A:89 6503 ( ?;NA)#8H>D8B ?8EB0 D; ?/M 500AA8O)$;5D0@>35;L 1 35;L D;.1535;L 2 35;L D;. 15: ?8B0=8O 0A-220-s-6-500 (530@>=,)#>;NAK %C0B> 803 (&8A8= D0@=2820 0,15 ! 1 (F. Hoffmann-La Roche)/>@01>@0 :0?A. 350@=0O :8A;>B0 ?>@. 103 (N@=0O 8A;>B0 -@ !?8@B>2>9 3% 25<; $;. (!0=:B-5B5@1C@3A:0O D0@@=0O 8A;>B0 -@ !?8@B>2>9 3% 25<; $;. ("25@A:0O D0@@=0O <07L 5% 253 ("25@A:0O D0@@> ;NA :@5@>20O @>20O AA8O)>@>20O 2 )!>@>20O <0B:0 :0?;8 50@>20O 9:0) D;.100@>20O 9:0) D;.50O@KH=8: ?;>4K D8;LB@-?0:5BK 2,83 !20 (5:A+)+>O@KH=8:0 =0AB>9:0 252A:0O D/D-:0)%>O@KH=8:0 0AB>9:0 25O@KH=8:0 ?;>4K 1003 (!B0@B-$8B>)"@0; 0<?. 5<; !5 (Micro Lab. Ltd.)&@0; B01. 500<3 !100 (Micro Lab. Ltd.)%@0; B01. 5002K9 75;5=. @-@ A?8@B. 1% 102;5=85 $)G@8;;80=B>2K9 75;5=. @-@ A?8@B. 1% 3<35:A8= 4 15@;8=-E5<8 @-@ 4/?@85<0 2=CB@L 4<3/5<; D;. 60<35:A8= 4<3/5<; 100<35:A8= B01. 4<:0@0 B01. 0,253 !30 (@18BA:89 %$),@>:@8?B8= B01. 2,5=E0;0<8= 10@53. 8 35@>=B>;.):@>=E0;8A-E5;L B01. !50 (Biologische Heilmittel Heel GmbH)1@>=E>-20:A>< :0?A. 3,5=E>-20:A>< :0?A. 7A;KE (OM Pharma))@>=E>-<C=0; :0?A. 3,5=E>-<C=0; :0?A. 7=E>1>A 5 % A8@>? 200 A=8O)"@>=E>;8B8= D;. 1253 (Sopharma AD)1@>=E>;8B8= D;. 1253 (Sopharma AD/ >AB10;:0=D0@=E>A0= :0?;8 25=E>AB0B 303 (;:>9 )#@>=E>F8= A8@>? 1253 (Balkanpharma)'@>B8=C< :0?;8 CH=K5 20% 103>@A:89 7-4  !);@CA=8:0 ;8AB D8;LB@-?0:5B 1,53 !10 (@0A=>3>@A:89 7-4  !)A@MAB :M9@ (1@5AB :0@5) :0?A. !100 (Nittany Pharmaceuticals Inc.)#C45=>D0;L: 3@>2L5 )C@0=0 B01. 200 ;8>D. 4/?@83. ACA?. 2/;>=3. 459AB28O 3.75<3 D;. !1 ($0@?0= AC??. 10= B01. 150;5=A:>5 D0@<. ?@54?@8OB85)(KAB@C<35;L 2,5% 5;L 503 BC10 (:@8E8=)(KAB@CD5 4;O ?>EC45=8O  (@>872>4AB2> <548:02))LNB8-B01A H0@ 4/<;045=F52 400<; (Bubchen)"N1E5= ;>G:> D;. 200 4/:C?0=8O <;045=F52 200B8; D;. 36% 503 (Polfa)070;0<8= 10AA8O).070?@>AB0= 0<?. 20@=K9 (203) ( 0AA25B :>AAAA8O)B075;8= @>AB@>8B5;L=K9 702>4)"075;8= "C10 253 8=4. C?. (!8=B57)$078;8? B01. ?/> 101@0; >@0;. @-@ 501@0; B01. !30 (Chiesi)'07>:0@48= 0,053 B01 !50 (Slovakofarma)(07>:0@48= B01. 100<3 !50 (Slovakofarma))0:A83@8? 0<? 0,5 <; !1 (Pasteur Merieux)T0:A83@8? H?@8F 0,570 (4/27@>A;KE 8 45B59 >B 3 ;5B 8 AB0@H5) (Aventis Pasteur)70 0.25; 0,5<; 070 ! 1 (<?@5?0@0B)<0:F8=0 - ! -  4/45B59 10<:3/0,5 @=528I0 A :>@=O3>@A:89 7-4  !)?0;5@80=0E5;L :0?;8 D;. 30<; (Biologische Heilmittel Heel GmbH)@=. D/? 1,53 !10 (@0A=>3>@A:;5:A@54AB20)@=. D/? 1,53 !20 (@0A=>3>@A:;5:A@54AB20)10=5>F8= >@. < 4/=0@C6. ?@8<. 103 %1 (Sandoz Gmbh) 2-79 icq wow dect desktop mobil cut .